Efficacy and safety of Qiangli Dingxuan tablet combined with amlodipine besylate for essential hypertension: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial

Background: Hypertension, a major cardiovascular risk factor, severely impacts patients’ quality of life. Qiangli Dingxuan tablet (QDT) is a formally approved Chinese patent medicine, which has been widely used as an adjunctive treatment for hypertension. This study aimed to investigate the antihype...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jianguo, Wang, Qingqing, Zhong, Dongsheng, Zhang, Jinju, Yuan, Tianhui, Wu, Hui, Li, Bin, Li, Shuangdi, Xie, Xiaoliu, An, Dongqing, Deng, Yue, Xian, Shaoxiang, Xiong, Xingjiang, Yao, Kuiwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363978/
https://www.ncbi.nlm.nih.gov/pubmed/37492087
http://dx.doi.org/10.3389/fphar.2023.1225529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363978/
https://www.ncbi.nlm.nih.gov/pubmed/37492087
http://dx.doi.org/10.3389/fphar.2023.1225529

Ejemplares similares